Eyenovia, Inc. (NASDAQ: HYPD) is a clinical‐stage ophthalmic pharmaceutical company devoted to developing precision microdose therapies for eye disorders. The company’s proprietary Optejet microdosing platform is designed to deliver consistent, low-volume liquid medication directly to the ocular surface, aiming to enhance treatment efficacy while reducing systemic exposure and side effects common to traditional eyedrop applications.
The company’s lead pipeline candidates focus on myopia progression in pediatric patients and presbyopia in adults. Eyenovia’s ultra-low-dose atropine formulation is being investigated for myopia control, and its pilocarpine-based microdose therapy targets accommodation loss in presbyopia. In addition, the firm is advancing combination microdose products for intraocular pressure management in glaucoma, all utilizing the Optejet system to ensure accurate and reproducible dosing.
Founded in 2015 and headquartered in New York with research facilities in Massachusetts, Eyenovia has conducted multiple clinical trials across North America, Europe, and Asia. The company partners with leading academic institutions and contract research organizations to support its regulatory strategy and to progress its candidates through pivotal study phases, with the goal of securing approvals in key global markets.
At the helm of Eyenovia is Chairman and Chief Executive Officer Robert Blum, whose background in ophthalmic drug development forms the cornerstone of the company’s scientific and commercial vision. The senior leadership team brings together expertise in clinical operations, regulatory affairs, and vision care innovation, positioning Eyenovia to potentially transform the standard of care in ophthalmology.
